EFTRW | eFFECTOR Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0030 - 0.0030
52 Week Range	0.0030 - 0.0030
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,500
Average Volume	N/A
Shares Outstanding	4,704,040
Market Cap	14,112
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-0.91
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	14
Country	USA
Website	EFTRW

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

EFTRW's peers: NRXPW, DRTSW, PRENW, ICUCW, HUMAW, JSPRW

*Chart delayed

Analyzing fundamentals for EFTRW we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see EFTRW Fundamentals page.

Watching at EFTRW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EFTRW Technicals page.